C14 Ceramide (d18:1/14:0)
| Code | Size | Price |
|---|
| TAR-T35803-5mg | 5mg | £124.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T35803-10mg | 10mg | £168.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T35803-25mg | 25mg | £287.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
C14 Ceramide is an endogenous ceramide generated by ceramide synthase 6. [1] During nutrient-deprivation-induced necroptosis in MEF cells, C14 ceramide levels increase in a time-dependent manner. [2] C14 ceramide plasma levels were reduced in obese patients with or without diabetes following a 12-week supervised exercise training program, correlating positively with weight and fat loss and negatively with an increase in insulin sensitivity. [3] In contrast, plasma levels were higher in Parkinson's disease patients with dementia than those without dementia and higher levels were correlated with deficits in memory.[4]
CAS:
34227-72-0
Formula:
C32H63NO3
Molecular Weight:
509.86
Purity:
0.98
SMILES:
CCCCCCCCCCCCCC=C[C@@H](O)[C@H](CO)NC(=O)CCCCCCCCCCCCC
References
Sundaram, K., Mather, A.R., Marimuthu, S., et al. Loss of neutral ceramidase protects cells from nutrient- and energy -deprivation-induced cell death. Biochem J. 473(6), 43-55 (2016).
Kasumov, T., Solomon, T.P., Hwang, C., et al. Improved insulin sensitivity after exercise training is linked to reduced plasma C14:0 ceramide in obesity and type 2 diabetes. Obesity (Silver Spring) 23(7), 1414-1421 (2015).
Grosch, S., Schiffmann, S., and Geisslinger, G. Chain length-specific properties of ceramides. Prog. Lipid Res. 51(1), 50-62 (2012).
Xing, Y., Tang, Y., Zhao, L., et al. Associations between plasma ceramides and cognitive and neuropsychiatric manifestations in Parkinson?s disease dementia. J. Neurol. Sci. 370, 82-87 (2016).